Early treatment with fluvoxamine may help prevent respiratory deterioration in patients with mild symptomatic COVID-19. In the trial, none of the patients who took fluvoxamine within 7 days of first symptoms developed serious breathing difficulties or required hospitalization for respiratory deterioration. The study was published online November 12 in the Journal of the American Medical Association.
The mechanism involves activation of the sigma-1 receptor.
Related Posts
